Pregnant women are excluded from this study; breastfeeding should be discontinued
Patients who are pregnant or breastfeeding are excluded from the study
Not pregnant or nursing, with negative serum pregnancy test; pregnant women are excluded from this study; breastfeeding should be discontinued; timeline: within 3 weeks prior to enrollment
Pregnant women are excluded from this study; breastfeeding must be discontinued
Pregnant or breastfeeding women will be excluded from participation in this trial
Patients may not be pregnant or nursing; pregnant women are excluded from this study; a negative pregnancy test must be documented 7 days or less prior to registration; breastfeeding must be discontinued prior to registration for this clinical trial
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women or lactating women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded; breastfeeding should be discontinued
Patients who are pregnant or breastfeeding will be excluded from the study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
Pregnant women are excluded; breastfeeding should be discontinued
Pregnant and breastfeeding women are excluded.
Pregnant or breastfeeding women are excluded from this study
Women who are pregnant or breastfeeding are excluded from the study
Pregnant women are excluded; breastfeeding should be discontinued prior to study entry
Pregnant women are excluded from this study; breastfeeding should be discontinued
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPregnant and breastfeeding women are excluded from this study
Pregnant or breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued for the duration of active study therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women are excluded from this study
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should also be avoided
Pregnant women are excluded from this study; breastfeeding should be discontinued while on study; patients who become pregnant while on study will be removed from the study once the pregnancy is confirmed
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should also be avoided
Patients who are pregnant or breastfeeding are excluded from the study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Pregnant women are excluded; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Pregnant or nursing (lactating) women; NOTE: Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should also be avoided
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinib
Pregnant or lactating women are excluded from this study; breastfeeding must be discontinued for eligibility
Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to beginning treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded; breastfeeding should be discontinued prior to entry onto the study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women; women desiring to become pregnant within the timeframe of the study are also excluded.
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to starting study treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued upon start of protocol therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if patient wishes to participate in study
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the study
Pregnant women or women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding is not allowed during study treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the study
Pregnant women are excluded from this study; breastfeeding should be discontinued at least two weeks prior to the start of PF-00299804 dosing
Pregnant women and women who are breastfeeding are excluded from this study
Pregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women are excluded; breastfeeding must be discontinued
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued
Pregnant or nursing women; breastfeeding must be discontinued prior to treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study and women who become pregnant while on study must be immediately discontinued; women who are breastfeeding will not be eligible for study participation
Pregnant women (admittedly, an unlikely event) are excluded from this study; breastfeeding should be discontinued
Pregnant and breastfeeding women are excluded from this study
Pregnant and breastfeeding women are not eligible for thyroidectomy and so are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or intention to get pregnant, or breastfeeding; pregnant women are excluded from this study; women who are breastfeeding will be excluded
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding mothers are also excluded from this study
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with ALA
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding must be discontinued.